Transaminase mutants and their applications

By performing amino acid mutation and combination mutation on ω-aminotransplant, expanding its substrate spectrum and improving stability, the problems of low activity and instability of existing ω-aminotransplants in industrial production are solved, and the efficient production of chiral amines is achieved and cost reduction.

CN115851649BActive Publication Date: 2024-12-03ASYMCHEM LAB TIANJIN
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
CN202210764588.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-04-21
Publication Date
2024-12-03
Estimated Expiration
2042-04-21

AI Technical Summary

Technical Problem

The existing ω-transaminases have problems with low catalytic activity, narrow substrate spectrum and instability in industrial production, which limits their application in the preparation of chiral amines.

Method used

By rationally designing and directed evolution of ω-transaminases, specific amino acid mutation sites are introduced, the substrate spectrum of enzymes is expanded, the catalytic capacity of large steric hindered substrates is improved, and stable under high concentrations of solvents and high temperature conditions are maintained. improves enzyme activity and selectivity.

Benefits of technology

The efficient production of adjuvant amines is achieved, and the production cost and post-processing difficulty is reduced, making the aminotransferase mutants suitable for industrial production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure QLYQS_1
    Figure QLYQS_1
  • Figure QLYQS_2
    Figure QLYQS_2
  • Figure QLYQS_3
    Figure QLYQS_3
Patent Text Reader

Abstract

The present invention discloses a transaminase mutant and its application. The transaminase mutant is obtained by mutation of the amino acid sequence shown in SEQ ID NO: 1, and the mutation includes at least: G292A; or the amino acid sequence of the transaminase mutant has a mutation site in the mutated amino acid sequence, and has an amino acid sequence with more than 80% homology with the mutated amino acid sequence, preferably 85% homology, and more preferably 90% homology. The above-mentioned transaminase mutant of the present invention expands the substrate spectrum of the enzyme and improves the catalytic ability of the enzyme to large steric hindrance substrates; at the same time, its stability is enhanced, and the catalytic reaction can be carried out under high concentration solvent and high temperature conditions; in addition, the stereoselectivity of the transaminase mutant is also greatly improved, and chiral amines can be produced more efficiently, reducing production costs and post-processing difficulties, and is suitable for promotion for industrial production of chiral amines.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biotechnology, and in particular to a transaminase mutant and an application thereof. Background Art

[0002] Chiral amines refer to a class of compounds with amino groups at the chiral center of small molecule compounds. They are key intermediates for many medicines and pesticides, and are receiving more and more attention in drug production and industrial and agricultural production. Among them, chiral amines are important intermediates for the synthesis of neurological drugs, cardiovascular drugs, antihypertensive drugs, anti-infective drugs and vaccines. At present, 40% to 50% of chiral drugs are chiral amine compounds. Efficient and convenient synthesis of chiral amine compounds is an important direction of organic synthetic chemistry research. For example, diabetes treatment drugs - sitagliptin (Merck and Codexis) and broad-spectrum contact herbicide - glufosinate (Bayer) both have chiral amine chemical modules.

[0003] At present, the methods for preparing chiral amines mainly include chemical method, biological resolution method and biological asymmetric synthesis method. Among them, the chemical synthesis of chiral amines often requires the use of expensive metal catalysts and special solvents, with high production costs, low enantioselectivity, and will cause certain environmental pollution; while the enzymatic preparation of chiral aromatic amines has the characteristics of high catalytic efficiency, strong stereoselectivity, mild reaction conditions, and environmental friendliness, which conforms to the general trend of green synthesis, and has become a hot spot in current research. At present, the enzymes used to prepare chiral aromatic amines are mainly lipases and transaminases. Compared with the maximum theoretical yield of high-purity chiral amines prepared by chiral resolution method using biocatalysts (lipases), the theoretical yield of biological asymmetric synthesis method (transaminases) is as high as 100%, so it has a strong application prospect in the production industry, and related research has received widespread attention. Among them, ω-transaminases (ω-TAs) have the advantages of high enantioselectivity and regioselectivity, a wide substrate spectrum, and no need to add expensive coenzymes, becoming one of the important industrial enzymes used in the production of chiral amines in industry.

[0004] Transaminase, also known as aminotransferase, belongs to the transferase class and can reversibly catalyze the amino transfer reaction between keto group and amino group. When the substrate or product of the transamination reaction catalyzed by this type of enzyme contains α-amino acid, the enzyme is called α-transaminase, otherwise it is called ω-transaminase. The product of α-transaminase is generally only α-amino acid, while ω-transaminase can aminate keto acid, aldehyde and ketone, and has the characteristics of high stereoselectivity and regenerative cofactors. Therefore, ω-transaminase is more widely used in the synthesis of pharmaceutical and pesticide intermediates. However, only a few wild ω-TAs reported so far can be directly used in the pharmaceutical industry, mainly due to the instability of the enzyme and unfavorable reaction equilibrium. Summary of the invention

[0005] The present invention aims to provide a transaminase mutant and application thereof to improve the activity of the transaminase.

[0006] In order to achieve the above object, according to one aspect of the present invention, a transaminase mutant is provided. The transaminase mutant is obtained by mutation of the amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes: G292A; or the amino acid sequence of the transaminase mutant has the mutation site in the mutated amino acid sequence, and has an amino acid sequence with more than 80% homology with the mutated amino acid sequence, preferably 85% homology, more preferably 90% homology, further preferably 95% homology, and even more preferably 99% homology.

[0007] According to another aspect of the present invention, a DNA molecule is provided, which encodes any one of the above aminotransferase mutants.

[0008] According to another aspect of the present invention, a recombinant plasmid is provided, which contains any one of the above-mentioned DNA molecules.

[0009] Further, the recombinant plasmid is pET-22a(+), pET-22b(+), pET-3a(+), pET-3d(+), pET-11a(+), pET-12a(+), pET-14b(+), pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), pET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31b(+), pET-32a(+), pET-35b (+), pET-38b(+), pET-39b(+), pET-40b(+), pET-41a(+), pET-41b(+), pET-42a(+), pET-43a(+), pET-43b(+), pET-44a(+), pET-49b(+), pQE2, pQE9, pQE30, pQE31, pQE3 2. pQE40, pQE70, pQE80, pRSET-A, pRSET-B, pRSET-C, pGEX-5X-1, pGEX-6p-1, pGEX-6 p-2, pBV220, pBV221, pBV222, pTrc99A, pTwin1, pEZZ18, pKK232-8, pUC-18 or pUC-19.

[0010] According to another aspect of the present invention, a host cell is provided, which contains the above-mentioned recombinant plasmid.

[0011] Furthermore, the host cell includes a prokaryotic cell or a eukaryotic cell; preferably, the prokaryotic cell is an Escherichia coli BL21-DE3 cell or an Escherichia coli Rosetta-DE3 cell; and the eukaryotic cell is a yeast.

[0012] According to another aspect of the present invention, a method for producing chiral amines is provided, which comprises the step of catalyzing a transamination reaction of a ketone compound and an amino donor by a transaminase, wherein the transaminase is any of the transaminase mutants described above.

[0013] Further, the ketone compound is Wherein, R1 is H, C1-C10 alkyl which is unsubstituted or optionally substituted by halogen, C5-C10 cycloalkyl which is unsubstituted or optionally substituted by halogen, C5-C10 aryl which is unsubstituted or optionally substituted by halogen, or C5-C10 heteroaryl; R2 is H, halogen, C1-C10 alkyl which is unsubstituted or optionally substituted by halogen, NH3, or NH3 protected by Boc or Cbz; R3 is C6-12 aryl which is unsubstituted or optionally substituted by halogen, or C3-6 heterocyclic group which is unsubstituted or optionally substituted by halogen; preferably, the ketone compound is

[0014] Furthermore, the amino donor is isopropylamine or alanine, preferably isopropylamine.

[0015] Furthermore, in the reaction system in which the transaminase catalyzes the transamination reaction of ketone compounds and amino donors, the pH is 7 to 11, preferably 8 to 10.5, and more preferably 10.5; preferably, the temperature of the reaction system in which the transaminase catalyzes the transamination reaction of ketone compounds and amino donors is 25 to 60°C, further preferably 30 to 55°C, and more preferably 50°C; preferably, the volume concentration of dimethyl sulfoxide in the reaction system in which the transaminase catalyzes the transamination reaction of ketone compounds and amino donors is 0% to 50%.

[0016] The above-mentioned transaminase mutant of the present invention is obtained by performing amino acid mutation and combined mutation of the protein on the basis of the transaminase shown in SEQ ID NO: 1 through rational design and directed evolution, so as to expand the substrate spectrum of the enzyme and improve the catalytic ability of the enzyme to large steric hindrance substrates; at the same time, its stability is enhanced, and the catalytic reaction can be carried out under high concentration solvent and high temperature conditions. Therefore, the application of this mutant can increase the reaction rate, improve the enzyme stability, reduce the enzyme dosage, and reduce the difficulty of post-treatment, so that it can be suitable for industrial production; in addition, the stereoselectivity of the transaminase mutant is also greatly improved, and chiral amines can be produced more efficiently, reducing the production cost and the difficulty of post-treatment, and it is suitable for promotion and use in the industrial production of chiral amines. DETAILED DESCRIPTION

[0017] It should be noted that, in the absence of conflict, the embodiments and features in the embodiments of the present application can be combined with each other. The present invention will be described in detail below in conjunction with the embodiments.

[0018] Transaminases are a type of biocatalyst based on proteins. In the industrial production process, they are often subjected to certain organic solvents, pressures, temperatures and other conditions that can easily denature proteins. Therefore, the biocatalysts used need to have high tolerance to meet the needs of industrial production. On the one hand, wild transaminases have low catalytic activity, a narrow substrate spectrum, and often have low tolerance to industrial demand conditions, which limits their wide application.

[0019] The present invention attempts to obtain mutants by performing amino acid mutations and combined mutations on proteins through rational design and directed evolution, thereby expanding the substrate spectrum of the enzyme and improving the catalytic ability of the enzyme for large steric hindrance substrates; at the same time, enhancing its stability so that it can perform catalytic reactions under high concentration solvent and high temperature conditions; and improving the stereoselectivity of the chiral center in the structure (1).

[0020] Rational modification of enzymes is to modify the substrate binding site, coenzyme binding site, surface and other sites of the enzyme based on the three-dimensional molecular structure of the enzyme to change the catalytic properties of the enzyme and improve enzyme activity, selectivity and other properties. Directed evolution of enzymes is an irrational design of proteins, which artificially creates special evolutionary conditions, simulates the natural evolution mechanism, modifies genes in vitro, applies error-prone PCR, DNA shuffling and other technologies, and combines efficient screening systems to obtain new enzymes with expected properties.

[0021] The present invention conducted substrate 1 analysis on 150 natural aminotransferases and 190 aminotransferase mutants available in the laboratory.

[0022] In order to expand the substrate spectrum of the enzyme, improve the catalytic ability of the enzyme to large steric hindrance substrates, and enhance its stability, the present application uses pET22b as an expression vector, introduces mutation sites on the transaminase by means of site-directed mutagenesis, saturation mutagenesis, error-prone PCR, and combined mutagenesis, obtains a plasmid containing a mutant gene, uses BL21 (DE3) as an expression strain, and obtains mutant proteins under the induction of IPTG. Then, the activity of the mutants is tested, and mutants with improved activity are selected.

[0023] Among them, site-directed mutagenesis refers to the introduction of desired changes (usually changes that characterize favorable directions) into target DNA fragments (which can be genomes or plasmids) through methods such as polymerase chain reaction (PCR), including addition, deletion, and point mutation of bases. Site-directed mutagenesis can quickly and efficiently improve the properties and characterization of target proteins expressed by DNA, and is a very useful method in genetic research.

[0024] The method of introducing site-directed mutations using whole plasmid PCR is simple and effective, and is currently the most commonly used method. The principle is that a pair of primers (forward and reverse) containing the mutation site are annealed with the template plasmid and then "circularly extended" by the polymerase. The so-called circular extension refers to the polymerase extending the primer according to the template, returning to the 5' end of the primer after one circle to terminate, and then undergoing repeated heating, annealing and extension cycles. This reaction is different from rolling circle amplification and will not form multiple tandem copies. After annealing, the extension products of the forward and reverse primers are paired to form an open-circular plasmid with a nick. The extension product is cut by Dpn I. Since the original template plasmid is derived from conventional Escherichia coli and is modified by dam methylation, it is sensitive to Dpn I and is chopped up, while the plasmid with the mutation sequence synthesized in vitro is not methylated and is not cut, so it can be successfully transformed in the subsequent transformation, and the mutant plasmid clone can be obtained.

[0025] The mutant plasmid was transformed into E. coli cells and overexpressed in E. coli. The optimal conditions for inducing transaminase expression were: 25°C, 0.1 mM IPTG induction overnight. Then, the crude enzyme was obtained by ultrasonically disrupting the cells.

[0026] Reaction verification conditions: Prepare substrate mother solution (substrate dissolved in DMSO) and PLP mother solution (10 mg 5-pyridoxal phosphate dissolved in 1 mL buffer), add boric acid buffer, PLP mother solution, 6 M isopropylamine hydrochloride solution, substrate mother solution in a 10 mL reactor in sequence, and finally add enzyme (20% enzyme solution), react at 200 rpm in a shaker, add acetonitrile to the reaction system after the reaction is completed, shake and mix well, centrifuge at 12000 rpm for 3 min, take the supernatant and dilute it to an appropriate multiple, and send it to HPLC to detect activity.

[0027] In the early stage, the transaminase was initially modified by a rational method of site-directed mutagenesis and single-point saturation mutagenesis, and the activity was verified using substrate 1: the reaction formula is as follows, and the results are shown in Table 1.

[0028]

[0029] Table 1

[0030]

[0031]

[0032]

[0033]

[0034] Remark:

[0035] 1) Reaction conditions A: 5wt enzyme, PLP 2mg, DMSO 20%, IPN 30eq, 500V, 0.1M Tris-Cl 9.0, 37°C, 40h;

[0036] 2) ND means no product formation was detected, - means 0-1%, + means 1-5%, ++ means 5-10%, +++ means 10-15%, and ++++ means >15%.

[0037] The above results show that the mutants modified by site-directed mutagenesis and directed evolution have acquired the catalytic ability for substrates with large steric hindrance, and the activity is gradually improved. In order to further improve the catalytic activity and stability of the mutants, the tolerance of the mutants was modified by saturation mutation, combined mutation and directed screening. The effect verification reaction is as follows, and the results are shown in Table 2.

[0038]

[0039] Table 2

[0040]

[0041]

[0042]

[0043] Remark:

[0044] 1) Reaction conditions B: 2wt enzyme, PLP 4mg, DMSO 30%, IPN 30eq, 200V, 0.1M boric acid 10.0, 50°C, 16h;

[0045] 2) Reaction conditions C: 0.5wt enzyme, PLP 4g / L, DMSO 30%, IPN 30eq, 100V, 0.1M boric acid 10.0, 50°C, 16h;

[0046] 3) Reaction conditions D: 0.5wt enzyme, PLP 1g / L, DMSO 30%, IPN 30eq, 100V, 0.1M boric acid 10.5, 55°C, 16h;

[0047] 4) Reaction conditions E: 0.1wt enzyme, PLP 1g / L, DMSO 50%, IPN 5eq, 100V, 0.2M boric acid 10.5, 60°C, 16h;

[0048] 5) ND means no product formation was detected, - means 0-10%, + means 10-20%, ++ means 20-50%, +++ means 50-80%, ++++ means 80-90%, and +++++ means >90%.

[0049] The mutants after the above tolerance modification were verified by the enzyme activity of substrate 1. The high temperature stability of the mutants was significantly improved. The optimal reaction temperature of Template was 37°C. The optimal reaction temperature of mutants such as T291A+G292A+T70C and mutants T291A+G292A+T70C+I160G was increased to 50°C. The optimal reaction temperature of mutants such as T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q and T291A+G292 The optimal reaction temperature of A+T70C+I160G+S204L+V244S+T134I+M326Q+Y158V was increased to 60℃; at the same time, the stability of the mutant in the solvent was also significantly improved, and the optimal reaction DMSO concentration was increased from 20% to 50%; and the enzyme activity was also continuously and gradually improved. The enzyme activity of the mutant T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q+Y158V was greatly improved compared with Template. In order to improve the stereoselectivity of the mutant, the selectivity of the mutant was modified by saturation mutation, combined mutation, error-prone PCR evolution and directional screening. The effect verification reaction is as follows, and the results are shown in Table 3.

[0050]

[0051] Table 3

[0052]

[0053]

[0054]

[0055]

[0056]

[0057] "-12aa" means removing the first 12 amino acids of the protein.

[0058] Remark:

[0059]

[0060] 1) ee value of transaminase mutant, ee value = ((CP1+CP)-(CP2+CP3)) / (CP+CP1+CP2+CP3)

[0061] 2) Reaction conditions D: 0.5wt enzyme, PLP 1g / L, DMSO 30%, IPN (isopropylamine hydrochloride) 30eq, 100V, 0.1M boric acid 10.5, 55°C, 16h;

[0062] 3) Reaction conditions F: 7wt enzyme, PLP 1g / L, DMSO 20%, IPN 30eq, 500V, 0.2M boric acid 10.5, 60°C, 16h;

[0063] 4) Reaction conditions G: 0.1wt enzyme, PLP 1g / L, DMSO 30%, IPN 10eq, 200V, 0.2M boric acid 10.5, 60°C, 16h;

[0064] 5) Reaction conditions H: 0.3wt enzyme, PLP 1g / L, DMSO 30%, IPN 10eq, 100V, 0.2M boric acid 10.5, 60°C, 16h;

[0065] 6) Reaction conditions L: 0.3wt enzyme, PLP 1g / L, DMSO 40%, IPN 10eq, 100V, 0.2M boric acid 10.5, 60°C, 16h;

[0066] 7) Reaction conditions M: 0.3wt enzyme, PLP 1g / L, DMSO 40%, IPN 10eq, 100V, 0.2M boric acid 10.5, 55°C, 16h;

[0067] 8) ND means no product formation was detected, - means 0-10%, + means 10-20%, ++ means 20-50%, +++ means 50-80%, ++++ means 80-90%, and +++++ means >90%;

[0068] 9) ND represents 0, * represents 0-10%, ** represents 10-50%, *** represents 50-80%, **** represents 80-90%, ***** represents 90-95%, and ****** represents >95%.

[0069] The above selectively modified mutants were verified by the enzyme activity of substrate 1. The selectivity of the mutants was gradually improved. The ee value of the mutant T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q+Y144L+G77L transaminase mutant was increased to more than 70%, and the mutant T291A+G292A+T70C+I160G+S204L+V244S+T1 34I+M326Q+Y144L+G77T, T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q+Y144L+G77T +L144W-12aa、T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q+Y144W+G77T+I165L-12 The ee value of aa aminotransferase mutants was increased to more than 80%, T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q+Y144W+G77T+I165L+A292S-12aa, T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q+Y144W+G77T+I165L+A292S-1 The ee value of the 5L+A292S+S278R-12aa transaminase mutant was increased to more than 90%, and the ee value of the T291A+G292A+T70C+I160G+S204L+V244S+T134I+M326Q+Y144W+G77T+I165L+A292S+S278R+Y69H+T70G+G160T+T106S-12aa transaminase mutant was increased to more than 95%.

[0070] By using software to perform computer simulation analysis on the three-dimensional structure of transaminase (Template), it was found that most of the mutation sites are located near the active center (the active center sites mainly include T70, Y144, A292, Y69, I160 and other sites). The mutation may enhance the binding of substrate and enzyme, thereby improving selectivity and catalytic efficiency.

[0071] According to a typical embodiment of the present invention, a transaminase mutant is provided. The amino acid sequence of the transaminase mutant is obtained by mutation of the amino acid sequence shown in SEQ ID NO: 1, and the mutation at least includes: G292A; or the amino acid sequence of the transaminase mutant has the mutation site in the mutated amino acid sequence, and has an amino acid sequence with more than 80% homology with the mutated amino acid sequence, preferably 85% homology, more preferably 90% homology, further preferably 95% homology, and even more preferably 99% homology.

[0072] The term "homology" as used herein has a meaning generally known in the art, and those skilled in the art are also familiar with the rules and standards for determining the homology between different sequences. The sequences defined by different degrees of homology in the present invention must also have improved tolerance of the transaminase to organic solvents. In the above embodiment, it is preferred that the amino acid sequence of the transaminase mutant has the above homology and has or encodes an amino acid sequence with improved tolerance to organic solvents. Those skilled in the art can obtain such variant sequences under the guidance of the disclosure of this application.

[0073] According to a typical embodiment of the present invention, a DNA molecule is provided. The DNA molecule encodes the above-mentioned organic solvent-resistant transaminase mutant. The above-mentioned transaminase mutant encoded by the DNA molecule has good organic solvent tolerance and high pH tolerance, and has high solubility expression characteristics and high activity characteristics.

[0074] The above-mentioned DNA molecules of the present invention can also exist in the form of "expression cassettes". "Expression cassettes" refer to linear or circular nucleic acid molecules, covering DNA and RNA sequences that can direct the expression of specific nucleotide sequences in appropriate host cells. In general, it includes a promoter that is effectively connected to the target nucleotide, which is optionally effectively connected to a termination signal and / or other regulatory elements. The expression cassette can also include sequences required for the correct translation of the nucleotide sequence. The coding region usually encodes the target protein, but also encodes a target functional RNA in the sense or antisense direction, such as antisense RNA or non-translated RNA. The expression cassette containing the target polynucleotide sequence can be chimeric, meaning that at least one of its components is heterologous to at least one of its other components. The expression cassette can also be naturally occurring, but obtained in an effective recombinant formation for heterologous expression.

[0075] According to a typical embodiment of the present invention, a recombinant plasmid is provided. The recombinant plasmid contains any of the above-mentioned DNA molecules. The DNA molecules in the recombinant plasmid are placed in the appropriate position of the recombinant plasmid so that the DNA molecules can be correctly and smoothly replicated, transcribed or expressed.

[0076] Although the qualifier used in the present invention to define the above-mentioned DNA molecules is "containing", it does not mean that other sequences unrelated to its function can be added at both ends of the DNA sequence at will. Those skilled in the art know that in order to meet the requirements of the recombination operation, it is necessary to add suitable restriction endonuclease cutting sites at both ends of the DNA sequence, or to add additional start codons, stop codons, etc. Therefore, if a closed expression is used to define it, it will not be able to truly cover these situations.

[0077] The term "plasmid" as used in the present invention includes any plasmid, cosmid, phage or Agrobacterium binary nucleic acid molecule in double-stranded or single-stranded linear or circular form, preferably a recombinant expression plasmid, which can be a prokaryotic expression plasmid or a eukaryotic expression plasmid, but preferably a prokaryotic expression plasmid. In certain embodiments, the recombinant plasmid is selected from pET-22a(+), pET-22b(+), pET-3a(+), pET-3d(+), pET-11a(+), pET- 12a(+), pET-14b(+), pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), pET-20b(+), pET-21a(+ ), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET -29a(+), pET-30a(+), pET-31b(+), pET-32a(+), pET-35b(+), pET-38b(+), pET-39b(+), pET-40b( +), pET-41a(+), pET-41b(+), pET-42a(+), pET-43a(+), pET-43b(+), pET-44a(+), pET-49b(+), pQ More preferably, the recombinant plasmid is pET-22b(+).

[0078] According to a typical embodiment of the present invention, a host cell is provided, the host cell containing any of the above-mentioned recombinant plasmids. The host cells suitable for the present invention include but are not limited to prokaryotic cells or eukaryotic cells. Preferably, the prokaryotic cell is a true bacterium, such as a Gram-negative bacterium or a Gram-positive bacterium. More preferably, the prokaryotic cell is an Escherichia coli BL21 cell or an Escherichia coli DH5α competent cell, and the eukaryotic cell is a yeast.

[0079] According to a typical embodiment of the present invention, a method for producing chiral amines is provided. The method comprises the step of catalyzing a transamination reaction of a ketone compound and an amino donor by a transaminase, wherein the transaminase is any of the above-mentioned organic solvent-resistant transaminase mutants. Since the above-mentioned transaminase mutant of the present invention has an expanded enzyme substrate spectrum and a high catalytic ability for large steric hindrance substrates; and at the same time, the stability is enhanced, and the catalytic reaction can be carried out under high concentration solvent and high temperature conditions, the application of this mutant can increase the reaction rate, improve the enzyme stability, reduce the enzyme dosage, and reduce the difficulty of post-treatment, so that it can be suitable for industrial production.

[0080] Further, the ketone compound is Wherein, R1 is H, C1-C10 alkyl which is unsubstituted or optionally substituted by halogen, C5-C10 cycloalkyl which is unsubstituted or optionally substituted by halogen, C5-C10 aryl which is unsubstituted or optionally substituted by halogen, or C5-C10 heteroaryl; R2 is H, halogen, C1-C10 alkyl which is unsubstituted or optionally substituted by halogen, NH3, or NH3 protected by Boc or Cbz; R3 is C6-12 aryl which is unsubstituted or optionally substituted by halogen, or C3-6 heterocyclyl which is unsubstituted or optionally substituted by halogen;

[0081] Preferably, the ketone compound is

[0082] In a typical embodiment of the present invention, the amino donor is isopropylamine or alanine, preferably isopropylamine.

[0083] In the reaction system in which the transaminase of the present invention is used to catalyze the transamination reaction of ketone compounds and amino donors, the pH is 7 to 10.5, preferably 8 to 10, and more preferably 9 to 10, that is, the pH value can be arbitrarily selected from 7 to 10.5, such as 7, 7.5, 8, 8, 8.6, 9, 10, 10.5, etc. The temperature of the reaction system in which the transaminase is used to catalyze the transamination reaction of ketone compounds and amino donors is 25 to 60° C., more preferably 30 to 55° C., and further preferably 40 to 50° C., that is, the temperature value can be arbitrarily selected from 25 to 60° C., such as 30, 31, 32, 35, 37, 38, 39, 40, 42, 45, 48, 50, 51, 52, 55, etc. The volume concentration of dimethyl sulfoxide in the reaction system in which the transaminase catalyzes the transamination reaction of ketone compounds and amino donors is 0% to 50%, for example, 10%, 15%, 18%, 20%, 30%, 35%, 38%, 40%, 42%, 48%, 49%, etc.

[0084] It is well known to those skilled in the art that many modifications can be made to the present invention without departing from the spirit of the present invention, and such modifications also fall within the scope of the present invention. The following experimental methods are conventional methods unless otherwise specified, and the experimental materials used can be easily obtained from commercial companies unless otherwise specified.

[0085] The beneficial effects of the present invention will be further described below in conjunction with embodiments.

[0086] Example 1

[0087] Template and mutants catalyze ketone compounds to generate chiral amines. The activity is tested under reaction condition M. The results show that Template has poor catalytic activity for substrates, while Template mutants have good catalytic activity, and the ee value of mutant T291A+G292A+I160G+S204L+V244S+T134I+M326Q+Y144W+G77T+I165L+A292S+S278R+Y69H+T70G+G160T+T106S-12aa transaminase mutant is increased to more than 90%. After the transformation of the present invention, the Template mutant obtains catalytic activity for substrates with large steric hindrance, the activity of some mutants is greatly improved, and the stereoselectivity of the mutant is also greatly improved, expanding the substrate spectrum. The reaction formula is as follows, and the results are shown in Table 4.

[0088]

[0089] Table 4

[0090]

[0091]

[0092] Remark:

[0093] 1) Reaction conditions M: 0.3wt enzyme, PLP 1g / L, DMSO 40%, IPN 10eq, 100V, 0.2M boric acid pH=10.5, 55°C, 16h;

[0094] 2) ND means no product formation was detected, - means 0-10%, + means 10-20%, ++ means 20-50%, +++ means 50-80%, ++++ means 80-90%, and +++++ means >90%.

[0095] 3) ND represents 0, * represents 0-10%, ** represents 10-50%, *** represents 50-80%, **** represents 80-90%, ***** represents 90-95%, and ****** represents >95%.

[0096] Example 2

[0097] Template and mutants catalyze ketone compounds to generate chiral amines. The activity is tested under reaction condition N. The results show that Template has no catalytic activity for the substrate, while Template mutants have good catalytic activity. After the modification of the present invention, Template mutants expand the catalytic substrate spectrum. The reaction formula is as follows, and the results are shown in Table 5.

[0098]

[0099] Table 5

[0100]

[0101]

[0102] Remark:

[0103] Reaction conditions M: 1wt enzyme, PLP 1g / L, DMSO 20%, IPN 10eq, 100V, 0.2M boric acid pH=10.5, 50°C, 16h;

[0104] ND means no product formation was detected, - means 0-10%, + means 10-20%, ++ means 20-50%, +++ means 50-80%, ++++ means 80-90%, +++++ means 90%-95%, and ++++++ means >95%.

[0105] Example 3

[0106] Template and mutants catalyze ketone compounds to generate chiral amines. The activity is tested under reaction condition N. The results show that Template has no catalytic activity for the substrate, while Template mutants have good catalytic activity. After the modification of the present invention, Template mutants expand the catalytic substrate spectrum. The reaction formula is as follows, and the results are shown in Table 6.

[0107]

[0108] Table 6

[0109]

[0110]

[0111] Remark:

[0112] Reaction conditions M: 1wt enzyme, PLP 1g / L, DMSO 20%, IPN 10eq, 100V, 0.2M boric acid pH=10.5, 50°C, 16h;

[0113] ND means no product formation was detected, - means 0-10%, + means 10-20%, ++ means 20-50%, +++ means 50-80%, ++++ means 80-90%, +++++ means 90%-95%, and ++++++ means >95%.

[0114] Example 4

[0115] Template and mutants catalyze ketone compounds to generate chiral amines. The activity is tested under reaction condition N. The results show that Template has no catalytic activity for the substrate, while the Template mutant has good catalytic activity. After the modification of the present invention, the Template mutant expands the catalytic substrate spectrum. The reaction formula is as follows, and the results are shown in Table 7.

[0116]

[0117] Table 7

[0118]

[0119]

[0120] Remark:

[0121] Reaction conditions M: 1wt enzyme, PLP 1g / L, DMSO 20%, IPN 10eq, 100V, 0.2M boric acid pH=10.5, 50°C, 16h;

[0122] 2) ND means that no product formation was detected, - means 0-20%, + means 20-40%, ++ means 40-60%, +++ means 60-80%, ++++ means 80-90%, and +++++ means 90-100%.

[0123] Example 5

[0124] Template and mutants catalyze ketone compounds to generate chiral amines. The activity is tested under reaction condition N. The results show that Template has no catalytic activity for the substrate, while the Template mutant has good catalytic activity. After the modification of the present invention, the Template mutant expands the catalytic substrate spectrum. The reaction formula is as follows, and the results are shown in Table 8.

[0125]

[0126] Table 8

[0127]

[0128] Remark:

[0129] Reaction conditions M: 1wt enzyme, PLP 1g / L, DMSO 20%, IPN 10eq, 100V, 0.2M boric acid pH=10.5, 50°C, 16h;

[0130] 2) ND means no product formation was detected, - means 0-10%, + means 10-20%, ++ means 20-50%, +++ means 50-80%, ++++ means 80-90%, and +++++ means >90%.

[0131] From the above description, it can be seen that the above embodiments of the present invention achieve the following technical effects: the mutant of the present invention expands the substrate spectrum of the enzyme and improves the catalytic ability of the enzyme for large steric hindrance substrates; at the same time, its stability is enhanced, and the catalytic reaction can be carried out under high concentration solvent and high temperature conditions. Therefore, the application of this mutant can increase the reaction rate, improve the enzyme stability, reduce the enzyme dosage, and reduce the difficulty of post-treatment, making it suitable for industrial production.

[0132] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention. Sequence Listing <110> Ailiying Pharmaceutical Group (Tianjin) Co., Ltd. <120> Transaminase mutants and their applications <130> PN186950KLY <150> CN202210426193.1 <151> 2022-04-21 <160> 2 <170> SIPOSequenceListing 1.0 <210> 1 <211> 350 <212> PRT <213> Sciscionella sp. <400> 1 Met Thr Thr Thr Glu Phe Ala Asn Arg Glu Ile His Met Thr Thr Thr 1 5 10 15 Glu Phe Ala Asn Ser Asn Leu Val Ala Val Glu Pro Val Ala Ile Arg 20 25 30 Glu Pro Thr Pro Pro Gly Ser Val Ile Gln Tyr Ser Glu Tyr Glu Leu 35 40 45 Asp Arg Ser His Pro Leu Ala Gly Gly Val Ala Trp Ile Glu Gly Glu 50 55 60 Tyr Val Pro Ala Asp Glu Ala Arg Ile Ser Ile Phe Asp Met Gly Phe 65 70 75 80 Tyr Thr Ser Asp Ala Thr Tyr Thr Gly Ile His Val Trp His Gly Asn 85 90 95 Ile Phe Arg Leu Glu Asp His Leu Asp Arg Leu Leu His Gly Ala Ala 100 105 110 Arg Leu Lys Leu Glu Thr Gly Met Ser Arg Glu Glu Leu Ala Gly Ile 115 120 125 Ala Lys Arg Cys Val Ser Leu Ser Gln Leu Arg Glu Ala Met Val Asn 130 135 140 Ile Thr Ile Thr Arg Gly Tyr Gly Ser Thr Pro Tyr Gly Arg Asp Ala 145 150 155 160 Thr Lys His Arg Pro Gln Val Tyr Val Tyr Ala Ile Pro Tyr Gln Trp 165 170 175 Ile Phe Pro Pro Glu Glu Gln Ile Phe Gly Thr Ser Val Ile Val Pro 180 185 190 Arg His Val Arg Arg Ala Gly Leu Asn Thr Ile Asp Pro Thr Ile Lys 195 200 205 Asn Phe Gln Trp Gly Asp Leu Ser Ala Ala Ile Arg Glu Ala His Asp 210 215 220 Arg Gly Ala Arg Ser Ala Val Leu Leu Asp Ala Asp Asn Cys Val Ala 225 230 235 240 Glu Gly Pro Gly Phe Asn Val Val Leu Val Lys Asp Gly Ala Leu Val 245 250 255 Ser Pro Ser Arg Asn Ala Leu Pro Gly Ile Thr Arg Lys Thr Val Tyr 260 265 270 Glu Ile Ala Ala Ala Lys Gly Ile Glu Thr Met Leu Arg Asp Val Thr 275 280 285 Ser Ser Glu Leu Tyr Glu Ala Asp Glu Leu Met Ala Val Ser Thr Gly 290 295 300 Gly Gly Val Thr Pro Ile Thr Ser Leu Asp Gly Glu Gln Val Gly Asn 305 310 315 320 Gly Glu Pro Gly Pro Ile Thr Val Ala Ile Arg Asp Arg Phe Trp Ala 325 330 335 Leu Met Asp Glu Pro Ser Ser Leu Ile Glu Ala Ile Asp Tyr 340 345 350 <210> 2 <211> 1053 <212> DNA <213> Sciscionella sp. <400> 2 atgaccacca ccgagtttgc caacagggaa ttccatatga ccaccaccga gtttgccaac 60 agcaatctgg tggccgtgga accggttgca atccgtgagc ctacccctcc gggcagcgtg 120 attcagtaca gcgagtacga actggatcgc agccatccgc tggcaggtgg cgttgcctgg 180 attgaaggcg agtatgttcc tgccgatgaa gcccgtatca gcatcttcga tatgggcttt 240 tataccagcg atgcgaccta taccgggatc cacgtttggc acggcaatat cttccgcctg 300 gaagaccacc tggaccgcct gctgcatggt gccgcacgtc tgaaactgga aaccggtatg 360 agccgcgaag aactggccgg cattgccaag cgttgtgtta gcctgagcca gctgcgcgaa 420 gccatggtga acatcaccat tacccgcggc tatggcagca ccccctacgg aagggatgcg 480 accaaacata ggccccaggt gtacgtgtat gccatcccgt atcagtggat cttccctccg 540 gaggaacaga ttttcggcac cagcgtgatt gtgccgcgtc atgtgcgccg cgccggtctc 600 aataccatcg acccgaccat caagaacttt cagtggggtg acctgtccgc cgccatccgt 660 gaggcccatg atcgcggcgc acgtagcgca gttctgctgg atgccgataa ttgcgtggcc 720 gagggtccgg gctttaatgt ggttctggtg aaggacggcg cactggtgag tccgagtcgt 780 aacgcactgc cgggcatcac ccgcaaaacc gtgtacgaaa tcgcagcagc caaaggcatc 840 gaaaccatgc tgcgcgacgt gaccagcagt gaactgtatg aggcagatga gctgatggcc 900 gtgagcaccg gaggtggtgt gacccctatt accagcctgg atggcgagca ggttggcaac 960 ggtgagccgg gcccgattac cgtggccatt cgtgatcgct tttgggcact gatggatgag 1020 ccgagcagcc tgattgaggc cattgactat taa 1053

Claims

1. A transaminase mutant, characterized in that: The transaminase mutant is obtained by mutation of the amino acid sequence shown in SEQ ID NO: 1, wherein the mutation is: G292A, and the first amino acid in SEQ ID NO. 1 is the first position after 12aa.

2. A DNA molecule, characterized in that The DNA molecule encodes the transaminase mutant according to claim 1.

3. A recombinant plasmid, characterized in that: The recombinant plasmid contains the DNA molecule according to claim 2.

4. The recombinant plasmid according to claim 3, characterized in that The recombinant plasmids are pET-22a(+), pET-22b(+), pET-3a(+), pET-3d(+), pET-11a(+), pET-12a(+), pET-14b(+), pET-15b(+), pET-16b(+), pET-17b(+), pET-19b(+), pET-20b(+), pET-21a(+), pET-23a(+), pET-23b(+), pET-24a(+), pET-25b(+), pET-26b(+), pET-27b(+), pET-28a(+), pET-29a(+), pET-30a(+), pET-31b(+), pET-32a(+), pET-35b(+ ), pET-38b (+), pET-39b (+), pET-40b (+), pET-41a (+), pET-41b (+), pET-42a (+), p ET-43a(+), pET-43b(+), pET-44a(+), pET-49b(+), pQE2, pQE9, pQE30, pQE31, pQE32 , pQE40, pQE70, pQE80, pRSET-A, pRSET-B, pRSET-C, pGEX-5X-1, pGEX-6p-1, pGEX-6 p-2, pBV220, pBV221, pBV222, pTrc99A, pTwin1, pEZZ18, pKK232-8, pUC-18 or pUC-19.

5. A host cell, characterized in that The host cell contains the recombinant plasmid according to claim 3 or 4, and the host cell does not include a plant cell.

6. The host cell according to claim 5, characterized in that The host cell includes a prokaryotic cell or a eukaryotic cell.

7. The host cell according to claim 6, characterized in that The prokaryotic cell is an Escherichia coli BL21-DE3 cell or an Escherichia coli Rosetta-DE3 cell; and the eukaryotic cell is a yeast.

8. A method for producing chiral amines, comprising the step of using a transaminase to catalyze a transamination reaction of a ketone compound and an amino donor, characterized in that: The transaminase is the transaminase mutant according to claim 1; the ketone compound is , , , or .

9. The method according to claim 8, characterized in that The amino donor is isopropylamine or alanine.

10. The method according to claim 9, characterized in that The amino donor is isopropylamine.

11. The method according to claim 8, characterized in that In the reaction system where the transaminase catalyzes the transamination reaction of ketone compounds and amino donors, the pH is 7-11.

12. The method according to claim 11, characterized in that In the reaction system where the transaminase catalyzes the transamination reaction of ketone compounds and amino donors, the pH is 8 to 10.

5.

13. The method according to claim 12, characterized in that In the reaction system where the transaminase catalyzes the transamination reaction of the ketone compound and the amino donor, the pH is 10.

5.

14. The method according to claim 11, characterized in that The temperature of the reaction system in which the aminotransferase catalyzes the transamination reaction of ketone compounds and amino donors is 25~60℃.

15. The method according to claim 14, characterized in that The temperature of the reaction system in which the aminotransferase catalyzes the transamination reaction of ketone compounds and amino donors is 30~55℃.

16. The method according to claim 15, characterized in that The temperature of the reaction system in which the aminotransferase catalyzes the transamination reaction of the ketone compound and the amino donor is 50°C.

17. The method according to claim 11, characterized in that The volume concentration of dimethyl sulfoxide in the reaction system in which the aminotransferase catalyzes the transamination reaction of ketone compounds and amino donors is 0%~50%.

Citation Information

Patent Citations

  • Transaminase mutant and application thereof

    CN110628742A